da Silva Mesquita R, Kyrylchuk A, de Oliveira R, Costa Sa I, Coutinho Borges Camargo G, Pontes G
PLoS One. 2020; 15(9):e0239364.
PMID: 32991579
PMC: 7523975.
DOI: 10.1371/journal.pone.0239364.
Maruca A, Moraca F, Rocca R, Molisani F, Alcaro F, Gidaro M
Molecules. 2020; 22(9).
PMID: 32961649
PMC: 6151421.
DOI: 10.3390/molecules22091571.
Zagorska A, Jaromin A
Molecules. 2020; 25(15).
PMID: 32717806
PMC: 7435667.
DOI: 10.3390/molecules25153337.
Gomez-Cadena A, Barreto A, Fioretino S, Jandus C
Cell Stress. 2020; 4(7):154-166.
PMID: 32656498
PMC: 7328673.
DOI: 10.15698/cst2020.07.224.
Mi Z, Gan B, Yu S, Guo J, Zhang C, Jiang X
J Enzyme Inhib Med Chem. 2019; 34(1):1489-1497.
PMID: 31416364
PMC: 6713216.
DOI: 10.1080/14756366.2019.1634703.
Harnessing Polypharmacology with Medicinal Chemistry.
Bolognesi M
ACS Med Chem Lett. 2019; 10(3):273-275.
PMID: 30891125
PMC: 6421528.
DOI: 10.1021/acsmedchemlett.9b00039.
Exploring the activity of polyamine analogues on polyamine and spermine oxidase: methoctramine, a potent and selective inhibitor of polyamine oxidase.
Di Paolo M, Cervelli M, Mariottini P, Leonetti A, Polticelli F, Rosini M
J Enzyme Inhib Med Chem. 2019; 34(1):740-752.
PMID: 30829081
PMC: 6407594.
DOI: 10.1080/14756366.2019.1584620.
Hybrids: a new paradigm to treat Alzheimer's disease.
Singh M, Kaur M, Chadha N, Silakari O
Mol Divers. 2015; 20(1):271-97.
PMID: 26328942
DOI: 10.1007/s11030-015-9628-9.
Multi-Target-Directed Ligands and other Therapeutic Strategies in the Search of a Real Solution for Alzheimer's Disease.
Agis-Torres A, Solhuber M, Fernandez M, Sanchez-Montero J
Curr Neuropharmacol. 2014; 12(1):2-36.
PMID: 24533013
PMC: 3915347.
DOI: 10.2174/1570159X113116660047.
Multi-target design strategies in the context of Alzheimer's disease: acetylcholinesterase inhibition and NMDA receptor antagonism as the driving forces.
Rosini M, Simoni E, Minarini A, Melchiorre C
Neurochem Res. 2014; 39(10):1914-23.
PMID: 24493627
DOI: 10.1007/s11064-014-1250-1.
Exploring different virtual screening strategies for acetylcholinesterase inhibitors.
Mishra N, Basu A
Biomed Res Int. 2013; 2013:236850.
PMID: 24294601
PMC: 3835907.
DOI: 10.1155/2013/236850.
7-Methoxytacrine-adamantylamine heterodimers as cholinesterase inhibitors in Alzheimer's disease treatment--synthesis, biological evaluation and molecular modeling studies.
Spilovska K, Korabecny J, Kral J, Horova A, Musilek K, Soukup O
Molecules. 2013; 18(2):2397-418.
PMID: 23429378
PMC: 6270602.
DOI: 10.3390/molecules18022397.
Insight into the binding interactions of CYP450 aromatase inhibitors with their target enzyme: a combined molecular docking and molecular dynamics study.
Galeazzi R, Massaccesi L
J Mol Model. 2011; 18(3):1153-66.
PMID: 21681442
DOI: 10.1007/s00894-011-1144-y.
Potent inhibitors of hepatitis C core dimerization as new leads for anti-hepatitis C agents.
Ni F, Kota S, Takahashi V, Strosberg A, Snyder J
Bioorg Med Chem Lett. 2011; 21(8):2198-202.
PMID: 21440437
PMC: 3086078.
DOI: 10.1016/j.bmcl.2011.03.014.
Memoquin: a multi-target-directed ligand as an innovative therapeutic opportunity for Alzheimer's disease.
Bolognesi M, Cavalli A, Melchiorre C
Neurotherapeutics. 2008; 6(1):152-62.
PMID: 19110206
PMC: 5084263.
DOI: 10.1016/j.nurt.2008.10.042.
